IRWD - Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

2024-06-20 13:00:43 ET

Summary

• Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024.
• The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032.
• NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support.
• Ironwood Pharmaceuticals had cash and cash equivalents of $121.5 million as of March 31st of 2024; Enough cash to fund its operations for at least the next 12 months.

Ironwood Pharmaceuticals, Inc. ( IRWD ) is expected to release data from a phase 2 study using CNP-104 for the treatment of patients with primary biliary cholangitis [PBC] in Q3 of 2024. This presents itself as one catalyst opportunity to look forward to this year. Another milestone to consider would be a New Drug Application [NDA] filing of apraglutide, which is being developed for the treatment of adult patients with short bowel syndrome [SBS] who are dependent on parenteral support [PS]. With positive phase 3 data on hand from the phase 3 STARS study for the treatment of patients with SBS-IF, it is in a position to not only file an NDA for these patients, but other regulatory applications across the globe....

For further details see: